跳至主要内容
临床试验/NCT05954325
NCT05954325已完成不适用

Extracorporal Apheresis Hannover Medical School Study in Post COVID-19 Patients

Hannover Medical School2 个研究点 分布在 1 个国家目标入组 63 人开始时间: 2023年8月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
63
试验地点
2
主要终点
Chalder Fatigue Scale

研究概览

简要总结

The complex clinical symptoms of post COVID syndrome, especially chronic fatigue, pose a major challenge to patients and to the health care system and are frequently refractory to therapeutic intervention. There is increasing evidence that a dysregulated post-viral immune response may be involved in the pathogenesis of post COVID syndrome. In uncontrolled case studies, an improvement of fatigue symptoms after removing autoantibodies has been reported in post COVID patients. However, there is a lack of prospective, sham controlled studies. We initiate an interventional, randomised, sham treatment-controlled prospective study, the EXTINCT post COVID study, which aims to scientifically test the therapeutic efficacy of an extracorporeal apheresis procedure (immunoadsorption) for the treatment of a well characterized cohort of patients with post COVID syndrome, while at the same time providing basic research evidence for an understanding of the pathogenesis of post COVID syndrome. Thereby, we expect to obtain important insights into the diagnosis, treatment and pathophysiology of post-COVID syndrome.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

盲法说明

double-blind

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18-75 years
  • Chronic Fatigue Syndrome (CFS) according to Canadian Consensus Criteria (at two time points > 4 weeks apart) with a duration of > 6 months with new onset < 12 weeks after PCR test confirmed SARS-CoV2-infection
  • Chalder Fatigue Scale >/= 4 binary scale (at two time points > 4 weeks apart)
  • Post exertional malaise >/= 14 h (at two time points > 4 weeks apart)
  • Bell Scale 20-50 (at two time points > 4 weeks apart)
  • Willing to comply with all aspects of the protocol, including blood draws, magnetic resonance imaging and ophthalmological evaluation
  • Patient is able to understand and fully participate in the activities of the study and consent in accordance with guidelines
  • Female patients of childbearing potential who are sexually active must be willing to use an acceptable form of contraception. Female patients must not be pregnant, planning to become pregnant, or be actively breastfeeding through the entire period.
  • Exclusion citeria:
  • Chronic fatigue due to other medical or psychological condition
  • Preexisting chronic fatigue prior to COVID infection
  • Oxygen requirement or ventilation during acute phase of COVID
  • Positive SARS-CoV-2-PCR test at the beginning of the study
  • Comorbidity bearing risk that patient might not tolerate treatment as judged by investigator including among others: malignant disease within the last 5 years, moderate to severe renal impairment (eGFR <60 ml/min), cardiac insufficiency (LVEF <40%), severe coronary heart disease, severe hypercoagulability
  • Acute or severe psychiatric disease
  • Active/acute infectious diseases like CMV, EBV, HBV, HCV, HIV, TBC
  • Patients who in the investigator's opinion might not be suitable for study (difficult peripheral venous access, not able to complete questionnaires e.g. due to language problems)
  • Taking immunosuppressive medication >3 weeks within 12 months before study inclusion
  • Any apheresis therapy before study inclusion
  • Contraindications for magnetic resonance imaging
  • Patients revealing abnormal brain structures visible in MR images
  • Patients with pre-existing ophthalmological condition or diabetes mellitus

排除标准

  • 未提供

研究组 & 干预措施

Immunoadsorption

Experimental

5 immunoadsorption treatments

干预措施: Immunoadsorption vs. sham immunoadsorption (Procedure)

Sham immunoadsorption

Sham Comparator

5 sham immunoadsorption treatments

干预措施: Immunoadsorption vs. sham immunoadsorption (Procedure)

结局指标

主要结局

Chalder Fatigue Scale

时间窗: 12 weeks

Time course of fatigue symptoms as determined based on Chalder Fatigue Scale (ranging from 0 to 33), higher values indicating a higher burden of fatigue symptoms

次要结局

  • Measure of health status(12 weeks)
  • Hand grip strength(12 weeks)
  • Cognitive Function(12 weeks)
  • Optical coherence tomography angiography(12 weeks)
  • Post exertional malaise symptoms(12 weeks)
  • Cranial magnetic resonance imaging and spectroscopy(12 weeks)
  • Symptoms related to chronic fatigue before and after immunoadsorption(12 weeks)
  • Depression and Anxiety(12 weeks)
  • Autonomic dysfunction(12 weeks)
  • 6-min. walk test(12 weeks)
  • Neurocognitive function(12 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Immunoadsorption vs. Sham Treatment in Post COVID-19... | 临床试验